Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Acadia Pharmaceuticals (Nasdaq: ACAD) will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 p.m. Eastern Time. The conference will be held virtually, and a live webcast of the presentation can be accessed on the company’s website under the investors section. An archived recording will be available for about one month post-event.

Acadia Pharmaceuticals specializes in advancing neural breakthroughs, having developed the first therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for Rett syndrome. Its clinical efforts are aimed at addressing symptoms of several central nervous system disorders, including schizophrenia and Alzheimer’s disease psychosis.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22^nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time.

The conference will be held virtually. A live webcast of the presentation will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For almost 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005229/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

FAQ

What date will Acadia Pharmaceuticals present at the Needham Virtual Healthcare Conference?

Acadia Pharmaceuticals will present on April 18, 2023.

What time is Acadia Pharmaceuticals scheduled to present?

The presentation is scheduled for 1:30 p.m. Eastern Time.

Where can I watch the Acadia Pharmaceuticals presentation?

The presentation can be accessed via a live webcast on Acadia's website.

What is the focus of Acadia Pharmaceuticals' clinical-stage development?

Acadia is focused on treating negative symptoms of schizophrenia, Alzheimer’s disease psychosis, and other neuropsychiatric disorders.

What innovative therapies has Acadia Pharmaceuticals developed?

Acadia has developed the first approved therapies for hallucinations and delusions associated with Parkinson's disease psychosis and for Rett syndrome.